
MSLE Stock Forecast & Price Target
MSLE Analyst Ratings
Bulls say
Satellos Bioscience is an attractive investment opportunity due to the company's promising novel drug development for Duchenne muscular dystrophy, evident in their trailblazing clinical study SAT-3247, with a potential for sustained functional benefit. With a projected future revenue of $502 million and a current cash reserve of $70 million, Satellos could generate favorable returns for investors. Key risks include clinical, regulatory, commercial, competition, and dilution, which the company plans to address through regular updates on the TRAILHEAD study's progress.
Bears say
Satellos Bioscience is currently a negative investment opportunity due to its lackluster financial performance. Its product sales, cost of sales, and collaboration revenue have all been consistently low, resulting in low total revenues and a lack of profitability. Until the company can improve its financials and show potential for growth, it is not a favorable investment for financial analysts.
This aggregate rating is based on analysts' research of Satellos Bioscience Inc and is not a guaranteed prediction by Public.com or investment advice.
MSLE Analyst Forecast & Price Prediction
Start investing in MSLE
Order type
Buy in
Order amount
Est. shares
0 shares